Pro Medicus (ASX:PME) FY21 result: Buy/hold/sell?
Patrick Melville
August 19, 2021
Pro Medicus Limited (ASX: PME) is the ASX share I wish I owned. After the latest FY21 result, what’s the verdict on its shares?
FY21 result: Is Pro Medicus (ASX:PME) the best ASX share?
Jaz Harrison
August 18, 2021
Could Pro Medicus Ltd (ASX:PME) be the best ASX share after the medical imaging healthcare company released its FY21 result?
FY22 trading update: Fisher & Paykel Healthcare (ASX:FPH) share price in focus
Jaz Harrison
August 18, 2021
The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price is in focus after releasing a trading update for FY22.
2 ways I analyse the ResMed (ASX: RMD) share price
Patrick Melville
August 8, 2021
The Resmed CDI (ASX: RMD) share price has been a star performer on the ASX recently. Here are just two ways I look at ResMed.
Why the Mesoblast (ASX:MSB) share price is under the spotlight
Jaz Harrison
July 30, 2021
The Mesoblast Limited (ASX:MSB) share price is under the spotlight right now on its FY21 fourth quarter.
Takeover: The Japara (ASX:JHC) share price is going bananas
Jaz Harrison
July 27, 2021
The Japara Healthcare Ltd (ASX:JHC) share price is going bananas and is up over 18% on the news of a takeover.
Q1 update: Why the Volpara (ASX:VHT) share price looks like a buy
Jaz Harrison
July 27, 2021
The Volpara Health Technologies Ltd (ASX:VHT) share price looks good to me after revealing more strong quarterly growth.
The Mach7 (ASX:M7T) share price is rising: Here’s why
Jaz Harrison
July 19, 2021
The Mach7 Technologies Ltd (ASX:M7T) share price is currently up after its contract win, with a business called Advocate Aurora.
The Volpara (ASX:VHT) share price is rising on genetics link-up
Jaz Harrison
July 19, 2021
The Volpara Health Technologies Ltd (ASX:VHT) share price is rising after revealing a partnership with a leading genetics company, Invitae.
Pro Medicus (ASX:PME) FY21 result: Buy/hold/sell?
August 19, 2021
Pro Medicus Limited (ASX: PME) is the ASX share I wish I owned. After the latest FY21 result, what’s the verdict on its shares?
FY21 result: Is Pro Medicus (ASX:PME) the best ASX share?
August 18, 2021
Could Pro Medicus Ltd (ASX:PME) be the best ASX share after the medical imaging healthcare company released its FY21 result?
FY22 trading update: Fisher & Paykel Healthcare (ASX:FPH) share price in focus
August 18, 2021
The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price is in focus after releasing a trading update for FY22.
2 ways I analyse the ResMed (ASX: RMD) share price
August 8, 2021
The Resmed CDI (ASX: RMD) share price has been a star performer on the ASX recently. Here are just two ways I look at ResMed.
Why the Mesoblast (ASX:MSB) share price is under the spotlight
July 30, 2021
The Mesoblast Limited (ASX:MSB) share price is under the spotlight right now on its FY21 fourth quarter.
Takeover: The Japara (ASX:JHC) share price is going bananas
July 27, 2021
The Japara Healthcare Ltd (ASX:JHC) share price is going bananas and is up over 18% on the news of a takeover.
Q1 update: Why the Volpara (ASX:VHT) share price looks like a buy
July 27, 2021
The Volpara Health Technologies Ltd (ASX:VHT) share price looks good to me after revealing more strong quarterly growth.
The Mach7 (ASX:M7T) share price is rising: Here’s why
July 19, 2021
The Mach7 Technologies Ltd (ASX:M7T) share price is currently up after its contract win, with a business called Advocate Aurora.
The Volpara (ASX:VHT) share price is rising on genetics link-up
July 19, 2021
The Volpara Health Technologies Ltd (ASX:VHT) share price is rising after revealing a partnership with a leading genetics company, Invitae.
Like our podcast? Get Owen's weekly newsletter.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.